New melioidosis death brings number of fatalities in Queensland this year to 35
Queensland Health said the death occurred in the Cairns and Hinterland region in the past seven days.
Another case was also recorded in the area in the same period.
This year to date, 237 people have been diagnosed with melioidosis in the stat
More than half of all cases have been recorded in the Cairns and Hinterland area, followed by the Townsville region.
The potentially deadly disease is prevalent in northern Australia, where the bacteria that causes it can be found in soil and water.
The bacteria can enter the body via cuts, inhalation or contaminated drinking water.
Outbreaks of the illness are often observed during the wet season or flooding.
Melioidosis is rare among healthy adults and children.
However, the risk is greater for people with health conditions such as diabetes or cancer.
Former NRL front rower Sam Backo remains in hospital after contracting melioidosis in Cairns in April.
James Cook University associate professor and microbiologist Jeffrey Warner said public awareness was limited due to a lack of knowledge about the disease.
Dr Warner said his team had begun a five-year study to better understand melioidosis.
"There's a lot we don't know about where the organism is in the environment [and] what preferred environment the organism requires for persistence," Dr Warner said.
Suggested causes for the outbreak include above-average rainfalls and the Bruce Highway upgrade.
Above-average rainfall hit north Queensland at the start of the year and by May, Townsville had recorded its wettest year on record.
Dr Warner said while there was a correlation between unprecedented rainfall in Townsville and where cases had occurred, the same could not be said for Cairns.
"There's something else going on here [in Cairns] and we're really interested in looking at the differences … between Townsville and Cairns," he said.
"Until we have a better handle on all of those things, we're not going to understand where it is, we're not going to understand who is vulnerable, we're not going to understand the individual behavioural issues that might be associated with acquisition.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
9 hours ago
- News.com.au
Shocking royal bombshell claim about Princess Margaret emerges in new book
An upcoming Princess Margaret biography has made a bombshell claim about her health. The book claims Queen Elizabeth II's younger sister suffered from fetal alcohol syndrome caused by Queen Elizabeth's drinking during pregnancy. The disorder — which develops when a child is exposed to alcohol while in the womb — can cause lifelong behavioural troubles and physical disabilities. Pulitzer-nominated Meryle Secrest, author of several biographies on notable people, writes in Princess Margaret and the Curse: An Inquiry into a Royal Life, that Margaret — who died in 2002 at the age of 71 due to a range of health issues, including several strokes — didn't have any physical symptoms related to the disorder, but did suffer from constant mood swings, migraines and learning deficiencies that could be connected to it. The royal author's book alleges that fetal alcohol syndrome could have played a significant role in the princess' personality. Princess Margaret was born in 1930, more 40 years before fetal alcohol syndrome was discovered in 1973. The book suggests that Queen Elizabeth, a known drinker, wasn't aware of the dangers or advised against drinking while pregnant as a result. The future Queen Elizabeth was 4 when her sister was born, but the Queen Mother was allegedly turned off by alcohol during her pregnancy with Elizabeth. 'The sight of wine simply turns me up! Isn't it extraordinary! It will be a tragedy if I never recover my drinking powers,' the Queen Mother wrote in a 1925 letter to her husband, according to The Telegraph. When Margaret entered the world on August 21, 1930, she was fourth in line to the British throne. Ahead of her were her uncle, Edward, Prince of Wales; her father, Albert, Duke of York, and her four-year-old sister, Elizabeth. That changed dramatically six years later, when Edward abdicated to marry an American divorcee and the girls' father ascended the throne. What didn't change was their governess: Marion 'Crawfie' Crawford cared for both Margaret and the big sister she called Lilibet, spilling the beans, to the royal family's irritation, in her 1950 memoir, The Little Princesses. 'Margaret was often naughty,' Brown quotes Crawfie as saying. 'She would often defy me with a sidelong look.' While noting that Lilibet was motherly towards Margaret, the latter's behaviour often made the future queen 'uneasy and filled with foreboding'. By her tweens, Margaret excelled at mimicry and was witty and sharp. But she could also be 'extremely tiresome,' Crawfie wrote, dawdling while dressing and 'pleased to know she kept us waiting'. It was a habit she never lost. 'For Lilibet, life was all about doing the right thing,' Brown said. 'For Margaret it was, and always would be, much more of a performance.' The king's death, at 56, exacerbated the already strained relationship between Margaret and the Queen Mother. Although they lived one floor apart in Clarence House until 1960, when Margaret married, they often communicated by letters delivered by their butlers. The Queen Mother reportedly disapproved of her daughter's all-day drinking and late-night socialising. According to Brown, Margaret's beverage of choice was vodka and orange, which she downed as a 'pick-me-up' at 12.30pm daily. She would have half a bottle of wine for lunch and then wait for the afternoon drinks tray, which her butler would wheel in at around 5.30pm. She'd have a cocktail or two, wine with dinner and then have several whiskies with Malvern water before bed at 2am.

Sydney Morning Herald
10 hours ago
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

The Age
10 hours ago
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.